1361225-40-2

Upstream product

• 1361221-43-3 5-((4-bromophenyl)sulfonyl)-2-chloropyridine 
• 106-53-6 para-bromobenzenethiol 
• 69045-79-0 2-choro-5-iodopyridine 
• 1361221-42-2 5-((4-bromophenyl)sulfanyl)-2-chloropyridine 
• 909532-22-5 5-((4-bromophenyl)sulfonyl)-2-pyridinamine 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1450622-07-7 2-(6-(4-((6-aminopyridin-3-yl)sulfonyl)phenyl)-5-(prop-1-yn-1-yl)pyridin-3-yl)-1,1,1,3,3,3-hexafluoropropan-2-ol 
• 1450622-08-8 2-(6-(4-((6-amino-3-pyridinyl)sulfonyl)phenyl)-5-cyclopropyl-3-pyridinyl)-1,1,1,3,3,3-hexafluoro-2-propanol 
• 1450622-09-9 2-(6-(4-((6-amino-3-pyridinyl)sulfonyl)phenyl)-5-(3-methoxy-1-propyn-1-yl)-3-pyridinyl)-1,1,1,3,3,3-hexafluoro-2-propanol 
• 1450622-10-2 (2R)-4-(2-(4-((6-amino-3-pyridinyl)sulfonyl)phenyl)-5-(2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl)-3-pyridinyl)-3-butyn-2-ol 
• 1450622-12-4 2-(6-(4-((6-amino-3-pyridinyl)sulfonyl)phenyl)-5-(3-((tert-butyl(dimethyl)silyl)oxy)-1-propyn-1-yl)-3-pyridinyl)-1,1,1,3,3,3-hexafluoro-2-propanol 
• 1450622-11-3 3-(2-(4-((6-amino-3-pyridinyl)sulfonyl)phenyl)-5-(2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl)-3-pyridinyl)-2-propyn-1-ol 
• 1450622-14-6 2-(6-(4-((6-amino-3-pyridinyl)sulfonyl)phenyl)-5-(3-methoxy-1-propyn-1-yl)-3-pyridinyl)-1,1,1-trifluoro-2-propanol 
• 1450622-18-0 2-(6-(4-((6-amino-3-pyridinyl)sulfonyl)phenyl)-5-(cyclopropylethynyl)-3-pyridinyl)-1,1,1-trifluoro-2-propanol 
• 1450622-21-5 (2R)-4-(2-(4-((6-amino-3-pyridinyl)sulfonyl)phenyl)-5-(2,2,2-trifluoro-1-hydroxy-1-methylethyl)-3-pyridinyl)-3-butyn-2-ol 
• 1450622-25-9 (2S)-4-(2-(4-((6-amino-3-pyridinyl)sulfonyl)phenyl)-5-(2,2,2-trifluoro-1-hydroxy-1-mthylethyl)-3-pyridinyl)-3-butyn-2-ol 
• 1450622-06-6 2-(6-(4-((6-amino-3-pyridinyl)sulfonyl)phenyl)-5-chloro-3-pyridinyl)-1,1,1,3,3,3-hexafluoro-2-propanol 

Relevant academic research and scientific papers

Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 5. A Novel Aryl Sulfone Series, Optimization Through Conformational Analysis

The glucokinase-glucokinase regulatory protein (GK-GKRP) complex plays an important role in controlling glucose homeostasis in the liver. We have recently disclosed a series of arylpiperazines as in vitro and in vivo disruptors of the GK-GKRP complex with

SULFONYL COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN

The present invention relates to sulfonyl compounds that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.